Therefore, the development of molecules that can block the molecular interaction between α-Syn and GSK-3β is necessary for devising effective therapeutics for neurodegenerative diseases that result from tau hyperphosphorylation. This evidence concerns the gene GSK3B and neurodegenerative disease.